2.16 USD
0 (0%)
2.25 USD
+0.09 (+4.17%)
Overall KPRX gets a fundamental rating of 3 out of 10. We evaluated KPRX against 192 industry peers in the Pharmaceuticals industry. KPRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KPRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KPRX had negative earnings in the past year.
KPRX had a negative operating cash flow in the past year.
KPRX had negative earnings in 4 of the past 5 years.
In the past 5 years KPRX reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -28.60%, KPRX is in line with its industry, outperforming 53.65% of the companies in the same industry.
Looking at the Return On Equity, with a value of -38.12%, KPRX is in line with its industry, outperforming 57.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.6% | ||
| ROE | -38.12% | ||
| ROIC | N/A |
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for KPRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KPRX has been increased compared to 1 year ago.
KPRX has more shares outstanding than it did 5 years ago.
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
KPRX has an Altman-Z score of -6.37. This is a bad value and indicates that KPRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.37, KPRX is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
There is no outstanding debt for KPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.37 |
ROIC/WACCN/A
WACC9.4%
2.3 Liquidity
KPRX has a Current Ratio of 8.79. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.79, KPRX is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
KPRX has a Quick Ratio of 8.79. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.79, KPRX is in the better half of the industry, outperforming 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.79 | ||
| Quick Ratio | 8.79 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.79% over the past year.
KPRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
Measured over the past years, KPRX shows a very strong growth in Revenue. The Revenue has been growing by 42.88% on average per year.
EPS 1Y (TTM)2.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.23%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, KPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.29% on average per year.
Based on estimates for the next years, KPRX will show a very strong growth in Revenue. The Revenue will grow by 32.09% on average per year.
EPS Next Y-267.71%
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue Next Year-91.05%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KPRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KPRX's earnings are expected to decrease with -59.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
5. Dividend
5.1 Amount
No dividends for KPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.16
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners19.58%
Inst Owner Change-10.66%
Ins Owners2.84%
Ins Owner Change0%
Market Cap7.95M
Revenue(TTM)N/A
Net Income(TTM)-8.54M
Analysts82.86
Price Target12.24 (466.67%)
Short Float %0.51%
Short Ratio0.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.91%
Min EPS beat(2)12.49%
Max EPS beat(2)101.33%
EPS beat(4)3
Avg EPS beat(4)13.09%
Min EPS beat(4)-85.38%
Max EPS beat(4)101.33%
EPS beat(8)5
Avg EPS beat(8)92.77%
EPS beat(12)8
Avg EPS beat(12)57.86%
EPS beat(16)9
Avg EPS beat(16)28.57%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.09%
PT rev (3m)9.09%
EPS NQ rev (1m)16.25%
EPS NQ rev (3m)10.67%
EPS NY rev (1m)32.28%
EPS NY rev (3m)29.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.35 | ||
| P/tB | 0.51 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.09
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-2.72
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS6.09
TBVpS4.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.6% | ||
| ROE | -38.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-52.66%
ROA(5y)-55.95%
ROE(3y)-106.19%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 61.39% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.79 | ||
| Quick Ratio | 8.79 | ||
| Altman-Z | -6.37 |
F-Score1
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.23%
EPS Next Y-267.71%
EPS Next 2Y-104.62%
EPS Next 3Y-59.01%
EPS Next 5Y40.29%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y42.88%
Sales Q2Q%N/A
Revenue Next Year-91.05%
Revenue Next 2Y-70.08%
Revenue Next 3Y-25.99%
Revenue Next 5Y32.09%
EBIT growth 1Y-216.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.13%
OCF growth 3YN/A
OCF growth 5YN/A
KIORA PHARMACEUTICALS INC / KPRX FAQ
What is the ChartMill fundamental rating of KIORA PHARMACEUTICALS INC (KPRX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KPRX.
What is the valuation status of KIORA PHARMACEUTICALS INC (KPRX) stock?
ChartMill assigns a valuation rating of 0 / 10 to KIORA PHARMACEUTICALS INC (KPRX). This can be considered as Overvalued.
Can you provide the profitability details for KIORA PHARMACEUTICALS INC?
KIORA PHARMACEUTICALS INC (KPRX) has a profitability rating of 1 / 10.
What is the expected EPS growth for KIORA PHARMACEUTICALS INC (KPRX) stock?
The Earnings per Share (EPS) of KIORA PHARMACEUTICALS INC (KPRX) is expected to decline by -267.71% in the next year.